Home > G. Tumoral pathology > RAS-driven cancer

RAS-driven cancer

Saturday 25 February 2012

KRAS-associated cancer; KRAS-driven oncogenesis; Cancer Harboring KRAS Mutations; Kras-driven tumor development; oncogenic KRAS-driven cancers; RAS mutant tumors

More than a third of all human cancers, including a high percentage of pancreatic, lung, and colorectal cancers, are driven by mutations and possibly amplification (increased copies) of RAS genes.

Types

- KRAS-driven cancer

- NRAS-driven cancer

  • NRAS-driven AML (30%)
  • NRAS-driven melanoma (15%)

- HRAS-driven cancer

  • HRAS-driven bladder cancer (15%)

Pathology

- KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. (23887294)

Links

- The NCI RAS Program

  • Developing ways to block RAS gene function has been a challenge.
  • NCI launched the RAS Program due to the magnitude of this challenge, as well as the potential clinical benefit.
  • The RAS gene family—which includes KRAS, HRAS, and NRAS—encodes for proteins involved in cell signaling.
  • When RAS genes are mutated, cells grow uncontrollably and evade signals to die. RAS mutations can also allow cells to resist available cancer therapies.

See also

- KRAS (Ki-ras, Kras)

References

- Dragging ras back in the ring. Stephen AG, Esposito D, Bagni RK, McCormick F. Cancer Cell. 2014 Mar 17;25(3):272-81. doi : 10.1016/j.ccr.2014.02.017 Review. PMID: 24651010

Portfolio